Takahama S, Washizaki A, Okamura T, Kitamura S, Nogimori T, Satou Y, Yasutomi Y, Yoshinaga T, Yamamoto T. J Virol. 2024 (accepted)
Selected peer-reviewed Publications
The quality of SIV-specific fCD8 T cells limits SIV RNA production in Tfh cells during antiretroviral therapy.
Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study
Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, Kazami Y, Washizaki A, Masuta Y, Suzuki R, Matsuda K, Komori M, Morey AL, Ishimoto K, Nakata M, Hasunuma T, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Sato N. Cell Rep Med. 2023 Aug 15;4(8):101134.doi: 10.1016/j.xcrm.2023.101134.
saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.
Komori M, Nogimori T, Morey AL, Sekida T, Ishimoto K, Hassett MR, Masuta Y, Ode H, Tamura T, Suzuki R, Alexander J, Kido Y, Matsuda K, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Akahata W.Nat Commun. 2023 May 19;14(1):2810. doi: 10.1038/s41467-023-38457-x.
Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses
Nishiyama A, Adachi Y, Tonouchi K, Moriyama S, Sun L , Aoki M, Asanuma H, Shirakura M, Fukushima A, Yamamoto T, Takahashi Y. Vaccine. 2023 Jul 12;41(31):4525-4533.doi: 10.1016/j.vaccine.2023.06.019. Epub 2023 Jun 15.
Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates.
Takahama S, Ishige K, Nogimori T, Yasutomi Y, Appay V, Yamamoto T.Mol Ther Methods Clin Dev. 2022 Dec 14;28:99-115. doi: 10.1016/j.omtm.2022.12.008. eCollection 2023 Mar 9
Principles governing establishment versus collapse of HIV-1 cellular spread.
Hataye JM, Casazza JP, Best K, Liang JC, Immonen TT, Ambrozak DR, Darko S, Henry AR, Laboune F, Maldarelli F, Douek DC, Hengartner NW, Yamamoto T, Keele BF, Perelson AS, Koup RA.Cell Host Microbe. 2019 Dec 11;26(6):748-763.e20. doi: 10.1016/j.chom.2019.10.006.
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies.
Adachi Y, Tonouchi K, Nithichanon A, Kuraoka M, Watanabe A, Shinnakasu R, Asanuma H, Ainai A, Ohmi Y, Yamamoto T, Ishii KJ, Hasegawa H, Takeyama H, Lertmemongkolchai G, Kurosaki T, Ato M, Kelsoe G, Takahashi Y.Nat Commun. 2019 Aug 28;10(1):3883. doi: 10.1038/s41467-019-11821-6.
STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques.
Yamamoto T*, Kanuma T, Takahama S, Okamura T, Moriishi E, Ishii KJ, Terahara K, Yasutomi Y. (*corresponding author)Sci Rep. 2019 Apr 11;9(1):5917. doi: 10.1038/s41598-019-42253-3.
The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T-cells.
Gutjahr A, Papagno L, Nicoli F, Kanuma T, Kuse N, Cabral-Piccin M, Rochereau N, Gostick E, Lioux T, Perouzel E, Price DA, Takiguchi M, Verrier B, Yamamoto T*, Paul S*, Appay V*. (*co-corresponding authors)JCI Insight. 2019 Apr 4;4(7). pii: 125107. doi: 10.1172/jci.insight.125107.
Elderly human hematopoietic progenitor cells express cellular senescence markers and are more susceptible to pyroptosis.
Fali T, Fabre-Mersseman V, Yamamoto T, Bayard C, Papagno L, Fastenackels S, Zoorab R, Koup RA, Boddaert J, Sauce D, Appay V.JCI Insight. 2018 Jul 12;3(13). pii: 95319. doi: 10.1172/jci.insight.95319.
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.
Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, Yamamoto T, Narpala S, Todd JP, Rao SS, McDermott AB, Koup RA, Rossmann MG, Mascola JR, Graham BS, Cohen JI, Nabel GJ.Cell. 2015 Aug 12. pii: S0092-8674(15)00959-9.
Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection
Yamamoto T, Lynch RM, Gautam R, Matus-Nicodemos R, Schmidt SD, Boswell KL, Darko S, Wong P, Sheng Z, Petrovas C, McDermott AB, Seder RA, Keele BF, Shapiro L, Douek DC, Nishimura Y, Mascola JR, Martin MA, Koup RA.Sci Transl Med. 2015 Jul 29;7(298):298ra120. (Selected Top 20 NIAID scientific highlights of fiscal year 2015)
Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization
Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, DarkoS, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D, NISC Comparative Sequencing Program, Nason M, Valiante NM, Malyala P, Gregorio ED, Barnett SW, Singh M, O’Hagan DT, Koup RA, Mascola1 JR, Martin MA, Kepler TB, Douek DC, Shapiro L, and Seder RA.Nat Commun. 2015 Apr 10;6:6565
HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.
Cooper A, García M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ.Nature. 2013 Jun 20;498(7454):376-9.
CD4 T follicular helper cell dynamics during SIV infection.
Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, Ambrozak DR, Sandler NG, Timmer KJ, Sun X, Pan L, Poholek A, Rao SS, Brenchley JM, Alam SM, Tomaras GD, Roederer M, Douek DC, Seder RA, Germain RN, Haddad EK, Koup RA.J Clin Invest. 2012 Sep 4; 122(9):3281-94.
Virus inhibition activity of effector memory CD8+ T cells determines Simian Immunodeficiency Virus load in vaccinated monkeys after vaccine breakthrough infection.
Yamamoto T, Johnson MJ, Price DA, Wolinsky DI, Almeida JR, Petrovas C, Nason M, Yeh WW, Shen L, Roederer M, Rao SS, McDermott AB, Lefebvre F, Nabel GJ, Haddad EK, Letvin NL, Douek DC, Koup RA.J Virol. 2012 May;86(10):5877-84.
Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T cell exhaustion in HIV infection.
Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer M, Gostick E, Katsikis PD, Douek DC, Haubrich R, Petrovas C, and Koup RA.Blood. 2011 May 5;117(18):4805-15. Epub 2011 Mar 11.
Selective transmission of R5 HIV-1 over X4 HIV-1 at the dendritic cell-T cell infectious synapse is determined by the T cell activation state.
Yamamoto T*, Tsunetsugu-Yokota Y*, Mitsuki YY, Mizukoshi F, Tsuchiya T, Terahara K, Inagaki Y, Yamamoto N, Kobayashi K, Inoue J. (*; equally contributed this work)PLoS Pathog. 2009 Jan;5(1):e1000279. Epub 2009 Jan 30.
Lentivirus vectors expressing short hairpin RNAs against the U3-overlapping region of HIV nef inhibit HIV replication and infectivity in primary macrophages.
Yamamoto T, Miyoshi H, Yamamoto N, Yamamoto N, Inoue J, Tsunetsugu-Yokota Y.Blood. 2006 Nov 15;108(10):3305-12.
Selected reviews
Pattern Recognition Receptor Ligands as an Emerging Therapeutic Agent for Latent HIV-1 Infection.
Shokichi Takahama and Yamamoto T*. (*corresponding author)Front Cell Infect Microbiol. 2020 May 8;10:216.
Phenotypic and Functional Analysis of Antigen-Specific T Cell Exhaustion.
Boswell KL, Yamamoto T*. (*corresponding author)Methods Mol Biol. 2017;1514:83-92. (Book Chapter)
HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection.
Lynch RM, Yamamoto T, McDermott AB.Curr Opin HIV AIDS. 2013 Jul;8(4):288-94.